Abstract
Purpose
Three major chemotherapy strategies have emerged in the treatment of PDAC in the recent past: multiple drug combination, stroma depletion, and use of nanodrug therapy. Anti-diabetic metformin was shown to improve the outcome of a number of cancer types the first seminal report on an observational study published in 2005 and the first hospital-based case–control study on pancreatic cancer in 2009.
Methods
In this review paper, we confront the findings of a selected number of epidemiological studies and clinical trials on the use of metformin in pancreatic cancer treatment with basic knowledge and research. We particularly emphasize on the point that contradictory clinical results likely originate from heterogeneous study design due to a trial and error approach rather than an evidence-based and scientific approach. A non-rigorous selection of patients suffering from PDAC and often a poor understanding of the biological mechanism of metformin coupled with lack of scientific data has led to general statements on metformin positive or negative action, another aspect which we highlight in the review.
Results
We here present a few pathways which in our opinion are predominant for pancreatic cancer specifically: mitochondrial activity, AMPK activation, mTOR inhibition, and decreased IGF-1R and HIF-1α expression.
Conclusion
We stress on the need for a better stratification of patients and a more rigorous planning of clinical trials not only focusing on classical parameters but also on potential predictive biomarkers (AMPK, mTOR, HIF-1α, IGF-1R) and metformin dosage for positive outcome.
Similar content being viewed by others
Abbreviations
- AKT:
-
Protein kinase B
- AMPK:
-
5′ Adenosine monophosphate-activated protein kinase
- APC:
-
Advanced pancreatic cancer
- EGF:
-
Epidermal growth factor
- ERK:
-
Extracellular signal-regulated kinase
- HIF-1α:
-
Hypoxia-inducible factor-1α
- HR:
-
Hormone receptor
- IGF:
-
Insulin-like growth factor
- IGF-1R:
-
Insulin-like growth factor 1 receptor
- INSR:
-
Insulin receptor
- mTOR:
-
Mammalian target of rapamycin
- MEK:
-
Mitogen-activated protein kinase
- MPC:
-
Metastatic pancreatic cancer
- NFκB:
-
Nuclear factor kappa B
- PI3K:
-
Phosphoinositide 3-kinase
- PTEN:
-
Phosphatase and tensin homologue
- SIAH:
-
Seven in abstensia homologue
- STAT3:
-
Signal transducer and activator of transcription 3
- T2DM:
-
Type 2 diabetes mellitus
References
Ahlin G, Chen L, Lazorova L et al (2011) Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J 11(6):400–411. doi:10.1038/tpj.2010.54
Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M (2011) Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30:1174–1182
Alvarez R, Musteanu M, Garcia-Garcia E et al (2013) Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109:926–933
Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP (2016) Effect of metformin use on survival in resectable pancreatic cancer: a single-institution experience and review of the literature. PLoS ONE 11(3):e0151632. doi:10.1371/journal.pone.0151632
Amgen (2012) Amgen announces termination of ganitumab phase 3 study for futility. In: Metastatic pancreatic cancer. http://www.prnewswire.com/news-releases/amgen-announces-termination-of-ganitumab-phase-3-study-for-futility-in-metastatic-pancreatic-cancer-165476446.html. Accessed 2 Apr 2016
Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC (2012) KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res 10:1228–1239. doi:10.1158/1541-7786.MCR-12-0340-T
Bailey P, Chang DK, Nones K et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52. doi:10.1038/nature16965
Bao B, Wang Z, Ali S et al (2012) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 5(3):355–364. doi:10.1158/1940-6207.CAPR-11-0299
Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh T-C, Wu E (2012) Advances in biomarker research for pancreatic cancer. Curr Pharm Des 18(17):2439–2451
Bhaw-Luximon A, Jhurry D (2015) New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: selective stroma depletion combined with nano drug delivery. Cancer Lett 369:266–273
Biankin AV, Waddell N, Kassahn KS et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399–405
Braghiroli MI, de Celis Ferrari ACR, Pfiffer TE et al (2015) Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. ecancer 9:563. doi:10.3332/ecancer.2015.563
Brahimi-Horn MC, Bellot G, Pouysségur J (2011) Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 21(1):67–72
Bridges HR, Jones AJ, Pollak MN, Hirst J (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462:475–487. doi:10.1042/BJ20140620
Cantoria MJ, Patel H, Boros LG, Meuillet EJ (2014) Metformin and pancreatic cancer metabolism, pancreatic cancer—insights into molecular mechanisms and novel approaches to early detection and treatment. In: Dr. Kelly McCall (ed) ISBN: 978-953-51-1375-1, InTech. doi:10.5772/57432. http://www.intechopen.com/books/pancreatic-cancer-insights-into-molecular-mechanisms-and-novel-approaches-to-early-detection-and-treatment/metformin-and-pancreatic-cancer-metabolism
Chai X, Chu H, Yang X, Meng Y, Shi P, Gou S (2015) Metformin increases sensitivity of pancreatic cancer cells to gemcitabine by reducing CD133+ cell populations and suppressing ERK/P70S6K signaling. Sci Rep 5: article number 14404. doi:10.1038/srep14404
Chaiteerakij R, Zhen DB, Burch PA et al (2015) Metformin use does not increase survival of pancreatic cancer patients: a cautionary lesson [abstract]. In: Proceedings of the 106th annual meeting of the American Association for Cancer Research; AACR, Cancer Res 75(15 Suppl):Abstract nr LB-183. doi:10.1158/1538-7445.AM2015-LB-183
Chandel N (2014) Four key questions about metformin and cancer. BMC Biol 12:8
Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia. J Biol Chem 275(33):25130–25138
Chari ST (2007) Detecting early pancreatic cancer: problems and prospects. Semin Oncol 34:284–294
Chen HX, Sharon E (2013) IGF-IR as an anti-cancer target—trials and tribulations. Chin J Cancer 32(5):242–252
Choi YK, Park K-G (2013) Metabolic roles of AMPK and metformin in cancer cells. Mol Cells 36:279–287. doi:10.1007/s10059-013-0169-8
Choi Y, Kim T-Y, Oh D-Y et al (2016) The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Res Treat 48(1):171–179
Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825. doi:10.1056/NEJMoa1011923
De Souza A, Khawaja KI, Masud F, Saif MW (2016) Metformin and pancreatic cancer: is there a role? Cancer Chemother Pharmacol. doi:10.1007/s00280-015-2948-8
DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3:1451–1461. doi:10.1158/1940-6207.CAPR-10-0157
Dell’Antone P (2012) Energy metabolism in cancer cells: how to explain the Warburg and Crabtree effects? Med Hypotheses 79(3):388–392. doi:10.1016/j.mehy.2012.06.002
Denduluri SK, Idowu O, Wang Z et al (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2:13e25
Deus CM, Santos GL, Loureiro R, Vega-Naredo I, Faneca H, Oliveira PJ (2015) Shutting down the furnace: preferential killing of cancer cells with mitochondrial-targeting molecules. Curr Med Chem 22(20):2438–2457
Esbah O, Eren T, Helvaci K et al (2014) The effect of metformin use on prognosis in pancreatic cancer patients. Acta Med Mediterr 30:465–471
Eser S, Schnieke A, Schneider G, Saur D (2014) Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 111:817–822. doi:10.1038/bjc.2014.215
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA (2012) The pancreas cancer microenvironment. Clin Cancer Res 18:4266–4276
Feng Y, Ke C, Tang Q et al (2014) Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis 5:e1088. doi:10.1038/cddis.2014.59
Fong ZV, Winter JM (2012) Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J 18(6):530–538. doi:10.1097/PPO.0b013e31827654ea
Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7(9):867–885
Gao Z-Y, Liu Z, Bi M-H et al (2016) Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med 11:1700–1706
García-Jiménez C, Gutiérrez-Salmerón M, Chocarro-Calvo A, García-Martinez JM, Castaño A, De la Vieja A (2016) From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer 114:716–722. doi:10.1038/bjc.2016.37
Gong J, Robbins LA, Lugea A, Waldron RT, Jeon CY, Pandol SJ (2014) Diabetes, pancreatic cancer, and metformin therapy. Front Physiol. doi:10.3389/fphys.2014.00426
Gong J, Kelekar G, Shen J, Shen J, Kaur S, Mita M (2016) The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Target Oncol. doi:10.1007/s11523-016-0423-z
Griss T, Vincent EE, Egnatchik R et al (2015) Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLoS Biol. doi:10.1371/journal.pbio.1002309
Hakam A, Fang Q, Karl R, Coppola D (2003) Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 48:1972–1978. doi:10.1023/A:1026122421369
Hardie DG, Alessi DR (2013) LKB1 and AMPK and the cancer-metabolism link—ten years after. BMC Biol 11:36. doi:10.1186/1741-7007-11-36
Higurashi T, Hosono K, Takahashi H, Komiya Y et al (2016) Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 17(4):475–483
Hirakawa T, Yashiro M, Murata A et al (2013) IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer 13:392
Hur KY, Lee M-S (2015) New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Investig 6(6):600–609. doi:10.1111/jdi.12328
Hwang AL, Haynes K, Hwang WT, Yang YX (2013) Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 42(7):1054–1059
Incio J, Suboj P, Chin SM et al (2015) Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. PLoS ONE 10(12):e0141392. doi:10.1371/journal.pone.0141392
Jeon S-M, Hay N (2012) The dark face of AMPK as an essential tumor promoter. Cell Logist 2(4):197–202
Jeon S-M, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485(7400):661–665. doi:10.1038/nature11066
Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS (2011) Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS ONE 6(11):e28068. doi:10.1371/journal.pone.0028068
Karna E, Surazynski A, Orlowski K, Laszkiewicz J, Puchalski Z, Nawrat P, Palka J (2002) Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol 83:239–245. doi:10.1046/j.1365-2613.2002.00237.x
Karnevi E, Said K, Andersson R, Rosendahl AH (2013) Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 13:235. doi:10.1186/1471-2407-13-235
Keane MG, Horsfall L, Rait G, Pereira SP (2014) A case–control study comparing the incidence of early symptoms inpancreatic and biliary tract cancer. BMJ Open 4:e005720. doi:10.1136/bmjopen-2014-005720
Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132–141. doi:10.1038/ncb2152
Kim JG, Kang MJ, Yoon YK et al (2012) Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS ONE 7(3):e33322. doi:10.1371/journal.pone.0033322
Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69(16):6539–6545. doi:10.1158/0008-5472.CAN-09-0418
Kisfalvi K, Moro A, Sinnett-Smith J, Eibl G, Rozengurt E (2013) Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 42(5):781–785. doi:10.1097/MPA.0b013e31827aec40
Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7:25–41
Kordes S, Pollak MN, Zwinderman AH et al (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. doi:10.1016/S1470-2045(15)00027-3
Kwon M, Choi YA, Choi MK, Song IS (2015) Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. Arch Pharm Res 38(5):849–856. doi:10.1007/s12272-014-0510-6
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011:11–20
Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137(2):482–488
Lipner MB, Marayati R, Deng Y, Wang X, Raftery L, O’Neil BH, Yeh JJ (2016) Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts. PLoS ONE 11(1):e0147113. doi:10.1371/journal.pone.0147113
Liu Z, Jia X, Duan Y, Xiao H, Sundqvist KG, Permert J et al (2013) Excess glucose induces hypoxia-inducible factor-1alpha in pancreatic cancer cells and stimulates glucose metabolism and cell migration. Cancer Biol Ther 14:428–435
Lodhia KA, Tienchaiananda P, Haluska P (2015) Understanding the key to targeting the IGF axis in cancer: a biomarker assessment. Front Oncol 5:142
Lonarardo E, Cioffi M, Sancho P et al (2013) Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS ONE. doi:10.1371/journal.pone.0076518
Lu Y, Rodrıguez LAG, Malgerud L et al (2015) New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. Br J Cancer. doi:10.1038/bjc.2015.353
Madiraju AK, Eion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546. doi:10.1038/nature13270
Magruder JT, Elahi D, Andersen DK (2011) Diabetes and pancreatic cancer chicken or egg? Pancreas 40:339–351
Mann KM, Ward JM, Yew CC et al (2012) Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 109:5934–5941
Maris C, D’Haene N, Trépant A-L et al (2015) IGF-IR: a new prognostic biomarker for human glioblastoma. Br J Cancer 113:729–737. doi:10.1038/bjc.2015.242
MAST Study—Metformin Active Surveillance Trial, ClinicalTrials.gov Identifier: NCT01864096
Mayer MJ, Klotz LH, Venkateswaran V (2015) Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis 18:303–309
Ming M, Sinnett-Smith J, Wang J et al (2014) Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells. PLoS ONE 9(12):e114573. doi:10.1371/journal.pone.0114573
Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV (2013) Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 6(6):649–659
Momi N, Kaur S, Krishn SR, Batra SK (2012) Discovering the route from inflammation to pancreatic cancer. Minerva Gastroenterol Dietol 58:283–297
Morran DC, Wu J, Jamieson NB et al (2014) Targeting mTOR dependency in pancreatic cancer. Gut 63:1481–1489. doi:10.1136/gutjnl-2013-306202
Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, Safe S (2014) Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem 289(40):27692–27701. doi:10.1074/jbc.M114.592576
Niraula S, Dowling RJO, Ennis M et al (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821–830. doi:10.1007/s10549-012-2223-1
O’Reilly T, McSheehy PMJ (2010) Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3(2):65–79
Owonikoko TK, Khuri FR (2013) Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book. doi:10.1200/EdBook_AM.2013.33.e395
Paplomata E, O’Regan R (2014) The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 6(4):154–166. doi:10.1177/1758834014530023
Park D-B (2015) Metformin promotes apoptosis but suppresses autophagy in glucose-deprived H4IIE hepatocellular carcinoma cells. Diabetes Metab J 39:518–527. doi:10.4093/dmj.2015.39.6.518
Pollak MN (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928. doi:10.1038/nrc2536
Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2(9):778–790
Pryor R, Cabreiro F (2015) Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J 471(Pt 3):307–322. doi:10.1042/BJ20150497
Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersenand GM, Tang AH (2015) Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1a pathway to predict survival in resectable pancreatic cancer. Br J Cancer 112:514–522. doi:10.1038/bjc.2014.659
Reni M, Dugnani E, Cereda S et al (2015) (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase 2 trial. Clin Cancer Res. doi:10.1158/1078-0432.CCR-15-1722
Rieder S, Michalski CW, Friess H, Kleeff J (2011) Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. Anti Cancer Agents Med Chem 11:427–433. doi:10.2174/187152011795677454
Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between insulin/IGF-1 and GPCR signaling systems: a novel target for the anti-diabetic drug metformin in pancreatic cancer. Clin Cancer Res 16(9):2505–2511
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 8:2905–2912
Sahra I, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576–3586
Sancho P, Burgos-Ramos E, Tavera A et al (2015) MYC/PGC-1a balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab 22:1–16
Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013) Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE 8(2):e57289. doi:10.1371/journal.pone.0057289
Song R (2016) Mechanism of metformin: a tale of two sites. Diabetes Care 39:187–189
Stark A, Eibl G (2015) Pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma. Pancreapedia: Exocrine Pancreas Knowledge Base. doi:10.3998/panc.2015.14
Subramani R, Lopez-Valdez R, Arumugam A et al (2014) Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PLoS ONE 9(5):e97016. doi:10.1371/journal.pone.0097016
Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35(12):2665–2673
Takahashi A, Kimura F, Yamanaka A et al (2014) Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int 14:53. doi:10.1186/1475-2867-14-53
Tan X-L, Bhattacharyya KK, Dutta SK et al (2015) Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. Pancreas 44(4):636–647, This article has a delayed release (embargo) and will be available in PMC on May 1, 2016
Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR (2001) AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61:589–593
Tomic T, Botton T, Cerezo M et al (2011) Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2:e199. doi:10.1038/cddis.2011.86
Trajkovic-Arsic M, Kalideris E, Siveke JT (2013) The role of insulin and IGF system in pancreatic cancer. J Mol Endocrinol 50:R67–R74
Utomo WK, Narayanan V, Biermann K, van Eijck CHJ, Bruno MJ, Peppelenbosch MP, Braat H (2014) mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Lett 346:309–317
Vasseur S, Tomasini R, Tournaire R, Iovanna JL (2010) Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. Cancers 2:2138–2152. doi:10.3390/cancers2042138
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA (2010) Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 9(18):3807–3814
Verma M (2010) Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology. Cancers 2:1830–1837. doi:10.3390/cancers2041830
Von Hoff DD, Ramanathan RK, Borad MJ et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548–4554
Wahdan-Alaswad R, Fan Z, Edgerton SM et al (2013) Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 12(24):3759–3769
Wang F, Herrington M, Larsson J, Permert J (2003) The relationship between diabetes and pancreatic cancer. Mol Cancer 2:4. doi:10.1186/1476-4598-2-4
Wang Z, Lai ST, Xie L et al (2014) Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 106(1):19–26
Wheaton WW, Weinberg SE, Hamanaka RB et al (2014) Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. doi:10.7554/eLife.02242
White E (2013) Exploiting the bad eating habits of Ras-driven cancers. Genes Dev 27:2065–2071
Xu J-W, Wang T-X, You L et al (2014) Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. PLoS ONE 9(3):e92847. doi:10.1371/journal.pone.0092847
Zhou X, Chen J, Yi G, Deng M, Liu H, Liang M, Shi B, Fu X, Chen Y, Chen L, He Z, Wang J, Liu J (2016) Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget 7(1):873–884. doi:10.18632/oncotarget.6418
Zulato E, Bergamo F, De Paoli A et al (2014) Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. Br J Cancer 111:25–32. doi:10.1038/bjc.2014.274
Acknowledgments
The authors are indebted to the Mauritius Research Council for funding drug delivery research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Bhaw-Luximon, A., Jhurry, D. Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. J Cancer Res Clin Oncol 142, 2159–2171 (2016). https://doi.org/10.1007/s00432-016-2178-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2178-4